Injectable hyaluronate-L- cysteine gel potentiates photothermal therapy in osteosarcoma via vorinostat-copper cell death.
Ontology highlight
ABSTRACT: The prognosis for osteosarcoma patients, a devastating malignancy affecting young individuals, remains grim despite multimodal therapeutic advances. Recently, the advent of cuproptosis, a novel programmed cell death, offers hope in fighting osteosarcoma. In this study, we introduce SAHAm@{[Cu(HA-Cys)2]Cl2}n, an injectable hyaluronate-L-cysteine hydrogel that integrates both copper ions (Cu2+) and vorinostat (SAHA) for the possible therapeutic effect. The Cu2+ targets the TCA cycle, inducing cuproptosis in osteosarcoma cells. While SAHA acts as both a histone deacetylase inhibitor and an ROS generator for eliminating tumor cells. The mechanism involves amplifying FDX-1 expression via SAHA modulation of the TCA cycle, which wa
SUBMITTER: Wang S
PROVIDER: S-EPMC11629197 | biostudies-literature | 2024 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA